Surgeon: Allen C. Ho, MD, FACS | Year: 2019
Dr. Ho delivers subretinal gene therapy to a patient with neovascular age-related macular degeneration (nAMD). Anterior and vitreous samples are taken to check for neutralizing antibodies to the viral vector. A vitrectomy is performed, then a 41-gauge microcatheter is used to deliver 250 microliters of viral vector into the subretinal space. The gene in this RegenXBio trial codes for an anti-VEGF protein, thereby creating an ocular biofactory to produce a protein similar to ranibizumab to control the nAMD.
Dr. Ho is a consultant for and receives grants from RegenXBio. This video features off-label use of RGX-314 gene therapy for nAMD.